Trypanosomiasis (Sleeping Sickness) Market

Market Overview:

The trypanosomiasis (sleeping sickness) market reached a value of USD 64.4 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 127.0 Million by ​2035​, exhibiting a growth rate (CAGR) of 6.39% during ​2025-2035​.

The trypanosomiasis (sleeping sickness) market has been comprehensively analyzed in IMARC's new report titled "Trypanosomiasis (Sleeping Sickness) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ​2025-2035​". Trypanosomiasis (sleeping sickness) is a serious type of parasitic infection that affects different parts of the body as it spreads, including the skin, blood, lymph nodes, brain, and the fluid surrounding the brain and spinal cord. The disease is caused by Trypanosoma brucei. Humans are infected with two types, including Trypanosoma brucei gambiense (TbG) and Trypanosoma brucei rhodesiense (TbR). TbG accounts for almost 92% of reported cases. Both are often spread through the bite of an infected tsetse fly and are most common in rural regions. The initial stage of the disease is marked by fevers, headaches, itching, and joint pains, which appear one to three weeks after the bite. Weeks or months later, the second stage begins with confusion, poor coordination, numbness, and difficulty sleeping. Diagnosing trypanosomiasis (sleeping sickness) commonly involves a comprehensive clinical assessment, medical history, and laboratory tests. The healthcare provider may also conduct Card Agglutination Test for Trypanosomiasis (CATT) for detecting antibodies against the parasite in the blood and for screening populations at risk for TbG infection.

The escalating prevalence of the protozoan parasite Trypanosoma brucei, which transmits to humans through the bite of infected tsetse flies (Glossina species) found only in sub-Saharan Africa, is primarily driving the trypanosomiasis (sleeping sickness) market. In addition to this, the inflating utilization of effective antiparasitic medications, such as pentamidine, suramin, and eflornithine, to inhibit parasitic enzymes and growth factors in individuals suffering from the ailment, is also creating a positive outlook for the market. Moreover, the widespread adoption of mini anion exchange centrifugation technique (mAECT), since it offers several benefits for disease diagnosis, including high sensitivity, applicability in field conditions, and the ability to examine a larger blood volume, is further bolstering the market growth. Apart from this, the rising usage of blood transfusion that restores red blood cell levels, improves oxygen delivery, and stabilizes critically ill patients, supporting recovery in patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of vector control methods, such as insecticide-treated traps, aerial spraying, and sterile insect techniques, to lower infection rates and prevent outbreaks is expected to drive the trypanosomiasis (sleeping sickness) market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the trypanosomiasis (sleeping sickness) market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for trypanosomiasis (sleeping sickness) and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the trypanosomiasis (sleeping sickness) market in any manner.

Recent Developments:

• In June 2024, the World Health Organization (WHO) included Fexinidazole Winthrop as the first-choice treatment for the acute form of sleeping sickness in its latest Guidelines for the treatment of human African trypanosomiasis.

Drugs:

Fexinidazole is a prodrug, which means it is inactive on its own but becomes active once digested by the parasite. The nitroreductase enzymes of the parasite activate fexinidazole, converting it into intermediates of extremely reactive amines. These reactive intermediates damage the parasite's DNA and proteins, interrupting vital cellular processes and resulting in death.

Time Period of the Study

• Base Year: 2024
• Historical Period: ​2019-2024​
• Market Forecast: ​2025-2035​

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the trypanosomiasis (sleeping sickness) market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the trypanosomiasis (sleeping sickness) market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current trypanosomiasis (sleeping sickness) marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the trypanosomiasis (sleeping sickness) market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the trypanosomiasis (sleeping sickness) market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the trypanosomiasis (sleeping sickness) market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035​) of trypanosomiasis (sleeping sickness) across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of trypanosomiasis (sleeping sickness) by age across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of trypanosomiasis (sleeping sickness) by gender across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with trypanosomiasis (sleeping sickness) across the seven major markets?
• What is the size of the trypanosomiasis (sleeping sickness) patient pool (​2019-2024​) across the seven major markets?
• What would be the forecasted patient pool (​2025-2035​) across the seven major markets?
• What are the key factors driving the epidemiological trend of trypanosomiasis (sleeping sickness)?
• What will be the growth rate of patients across the seven major markets?

Trypanosomiasis (Sleeping Sickness): Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for trypanosomiasis (sleeping sickness) drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the trypanosomiasis (sleeping sickness) market?
• What are the key regulatory events related to the trypanosomiasis (sleeping sickness) market?
• What is the structure of clinical trial landscape by status related to the trypanosomiasis (sleeping sickness) market?
• What is the structure of clinical trial landscape by phase related to the trypanosomiasis (sleeping sickness) market?
• What is the structure of clinical trial landscape by route of administration related to the trypanosomiasis (sleeping sickness) market?